17th Congress of EHA

Education Sessions follow a common principle and concentrate on one topic. Three aspects of the topic are discussed: basic research; translational research; and clinical aspects.

 

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Chair: A Biondi, Monza, Italy

• MRD diagnostics in ALL treatment protocols: choice of technique and need for standardization
  JJM van Dongen, Rotterdam, The Netherlands
• Genomic analysis of ALL
  C Mulligan, Memphis, USA
• Novel approaches for therapy of resistant ALL
  R Bassan, Venice, Italy

 

ACUTE MYELOID LEUKEMIA (AML)
Chair: H Serve, Frankfurt, Germany

• AML biology
  R Delwel, Rotterdam, The Netherlands
• Mutation analysis
  C Thiede, Dresden, Germany
• Optimal AML therapy in 2012
  H Dombret, Paris, France

 

BLEEDING DISORDERS
Chair: F Leebeek, Rotterdam, The Netherlands

• Regulation of coagulation by the fibrinolyic system
  KA Hajjar, New York, USA
• How to assess the bleeding phenotype in children and adults: epitomes from inherited bleeding disorders and immune thrombocytopenia
  F Rodeghiero, Vicenza, Italy
• Acquired hemophilia: pathogenesis and treatment
  P Collins, Cardiff, United Kingdom

 

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Chair: S Stilgenbauer, Ulm, Germany

• Development and evolution of CLL
  N Chiorazzi, Manhasset, USA
• Standard & Novel Treatments in first line and in relapse/refractory Situation
  P Hillmen, Leeds, United Kingdom
• Allo-SCT: why, how & when?
  C Moreno, Barcelona, Spain

 

CHRONIC MYELOID LEUKEMIA (CML)
Chair: A Hochhaus, Jena, Germany

• New insights into CML biology
  D Perrotti, Columbus, USA
• Mutations that confer resistance to therapy
  J Duyster, Munich, Germany
• New approaches to treatment of CML
  G Saglio, Orbassano, Italy

 

COAGULATION PROBLEMS IN INTENSIVE CARE
Chair: I Pabinger, Vienna, Austria

• The coagulopathy of trauma and massive perioperative bleeding
  D Bolliger, Basel, Switzerland
• Diagnosis and treatment of DIC
  CH Toh, Liverpool, United Kingdom
• Heparin induced thrombocytopenia
  A Greinacher, Greifswald, Germany

 

HODGKIN'S LYMPHOMA
Chair: S Proctor, Newcastle upon Tyne, United Kingdom

• Molecular pathology of Hodgkin´s Lymphoma and prognostic implications
  R Gascoyne, Vancouver, Canada
• Radiotherapy in Hodgkin's Lymphoma: which dose and for whom
  A Engert, Cologne, Germany
• New drugs in the treatment of relapsed / refractory Hodgkin's Lymphoma
  A Younes, Houston, USA

 

BORDERLAND BETWEEN DLBCL AND BURKITT'S LYMPHOMA
Chair: L Trümper, Göttingen, Germany

• Pathology on B-cell lymphomas with features intermediate between DLBCL and Burkitt lymphoma
  A Jack, Leeds, United Kingdom
• MYC-positive lymphomas other than Burkitt Lymphoma
  R Siebert, Kiel, Germany
• How to treat patients with borderline DLBCL and Burkitt lymphoma
  J Sweetenham, Cleveland, USA

 

MULTIPLE MYELOMA (MM)
Chair: P Sonneveld, Rotterdam, The Netherlands

• Biological characterization of MM
  F Davies, London, United Kingdom
• Old and new treatments (non-transplant)
  MV Mateos, Salamanca, Spain
• Autologous and allogeneic transplantation in the novel agent era
  M Cavo, Bologna, Italy

 

MYELODYSPLASTIC SYNDROMES (MDS)
Chair: M Lübbert, Freiburg, Germany

• Biology of MDS
  B Ebert, Boston, USA
• Integration of somatic mutations in diagnosis and risk assessment in MDS
  L Malcovati, Pavia, Italy
• MDS: clinical aspects
  N Gattermann, Düsseldorf, Germany

 

MYELOPROLIFERATIVE DISORDERS (MPD)
Chair: C Harrison, London, United Kingdom

• Biology of MPNs
  W Vainchenker, Villejuif, France
• Erythrocytosis
  MF McMullin, Belfast, Northern Ireland
• New approaches to therapy
  JJ Kiladjian, Paris, France

 

PEDIATRIC HEMATOLOGY
Chair: R Somech, Tel Hashomer, Israel

• The pathogenesis of primary immunodeficiencies
  M van der Burg, Rotterdam, The Netherlands
• EBV hypersensitivity syndromes
  A Borkhardt, Düsseldorf, Germany
• Therapy of primary immundeficiencies: Promises and culprits of gene therapy
  M Cavazzana-Calvo, Paris, France

 

PLATELETS
Chair: D Perry, Cambridge, United Kingdom

• Recent advances in platelet signalling and the control of hemostasis and thrombosis
  A Poole, Bristol, United Kingdom
• Inherited platelet disorders
  C van Geet, Leuven, Belgium
• Old and new P2Y12 inhibitors: any role for laboratory monitoring?
  M Cattaneo, Milan, Italy

 

RED CELL DISEASE
Chair: A Taher, Beirut, Lebanon

• Manipulating erythropoiesis in animal models of beta-thalassemia
  S Rivella, New York, USA
• Genetic modifiers of thalassemia
  R Galanello, Cagliari, Italy
• Assessing iron overload and toxicity
  J Porter, London, United Kingdom

 

STEM CELL TRANSPLANTATION
Chair: P Jacobs, Cape Town, South Africa

• T-cell reconstitution after hematopoietic stem cell transplantation
  M van den Brink, New York, USA
• Mesenchymal stem cell therapy
  W Fibbe, Leiden, The Netherlands
• Donor lymphocyte infusions: immunological and clinical aspects
  F Falkenburg, Leiden, The Netherlands

 

THROMBOSIS
Chair: A Falanga, Bergamo, Italy

• Role of coagulation in atherothrombosis
  H ten Cate, Maastricht, The Netherlands
• Detection and role of circulating microparticles in thrombosis
  N Key, Chapel Hill, USA
• Prevention of venous thromboembolism
  A Cohen, London, United Kingdom

 

TRANSFUSION
Chair: J Storry, Lund, Sweden

• Transfusion medicine: scanning the horizon
  S Dzik, Boston, USA
• In vitro genetic manipulation of erythrocyte antigens
  C Bagnis, Marseille, France
• Fetal/neonatal alloimmune thrombocytopenia
  J Kjeldsen-Kragh, Lund, Sweden

 

UNUSUAL LYMPHOMAS
Chair: C Thieblemont, Paris, France

• Intravascular large B-cell lymphoma
  AJM Ferreri, Milan, Italy
• Diagnosis and managing of  "in situ" lymphomas
  A López-Guillermo, Barcelona, Spain
• Treatment of splenic lymphomas
  E Iannitto, Taranto, Italy

Hematology-in-Focus sessions concentrate on a hot scientific or clinical topic in any field of hematology. The sessions are designed to examine the topic in-depth.

 

ACUTE MEGAKARYOBLASTIC LEUKEMIA (AMKL)
Chair: W Vainchenker, Villejuif, France

• AMKL molecular pathogenesis
  T Mercher, Villejuif, France
• Differentiation therapy AMKL
  J Crispino, Chicago, USA

 

AML PATHOGENESIS
Chair: J Cools, Leuven, Belgium

• MN1 associated AML
  M Heuser, Hannover, Germany
• MLL inhibitors
  B Huntly, Cambridge, United Kingdom

 

AUTOPHAGY
Chair: T Holyoake, Glasgow, United Kingdom

• Regulation of autophagy by phosphorylation
  I Dikic, Frankfurt, Germany
• Autophagy in MDS
  K Simon, Oxford, United Kingdom

 

CLL BIOLOGY & PATHOGENESIS
Chair: E Montserrat, Barcelona, Spain

• B-cell receptors and microenvironment
  F Caligaris-Cappio, Milan, Italy
• Genomic landscape of somatic mutations in CLL
  E Campo, Barcelona, Spain

 

INHERITED BLEEDING DISORDERS: NEW DEVELOPMENTS IN TREATMENT & SAFETY
Chair: M Peters, Amsterdam, The Netherlands

• Systems to monitor treatment safety in inherited bleeding disorders
  M Makris, Sheffield, United Kingdom
• New treatment options in hemophilia
  B Sørensen, London, United Kingdom

 

LEUKEMIA STEM CELLS
Chair: D Grimwade, London, United Kingdom

• Founding clones and evolving subclones: insights in AML from next-generation sequencing
  J Welch, St Louis, USA
• Stem cells and leukemic stem cells in C/EBPα mutant AML
  C Nerlov, Edinburgh, United Kingdom

 

LYMPHOPOIESIS
Chair: E Macintyre, Paris, France

• BCL6 and lymphopoiesis
  A Melnick, New York, USA
• BCL11a and BCL11b in lymphopoiesis
  P Liu, Cambridge, United Kingdom

 

MALIGNANCY ASSOCIATED THROMBOSIS
Chair: T Barbui, Bergamo, Italy

• Alternatively splised tissue factor in tumor growth
  H Versteeg, Leiden, The Netherlands
• Glycosaminoglycan interactions with integrins and selectins regulate tumor metastasis
  L Borsig, Zürich, Switzerland

 

MONOCLONAL GAMMOPATHY
Chair: R Hajek, Brno, Czech Republic

• Novel diagnostic tools in amyloidosis
  G Merlini, Pavia, Italy
• POEMS syndrome - diagnosis and treatment
  MA Dimopoulos, Athens, Greece

 

NEONATAL HEMATOLOGY
Chair: S Izraeli, Tel Hashomer, Israel

• Neonatal hematology in Down's Syndrome
  I Roberts, London, United Kingdom
• Bone marrow failures in infancy
  H Tamary, Peta Tikva, Israel

 

PRODUCTION OF RED CELLS
Chair: S Constantinescu, Brussels, Belgium

• From erythroid commitment to enucleation
  H Lodish, Cambridge, USA
• Regulation by apoptosis in RBC
  O Hermine, Paris, France

 

RECENT ADVANCES IN MDS
Chair: D Birnbaum, Marseille, France

• SF3B1
  P Campbell, Hinxton, United Kingdom
• Clonal hierarchy of MDS and AML
  T Graubert, St Louis, USA

 

TET MUTATIONS AND LEUKEMIA
Chair: I Touw, Rotterdam, The Netherlands

• Biological consequences of TET2 mutations
  O Bernard, Villejuif, France
• TET proteins and 5-hydroxymethylation
  H Stunnenberg, Nijmegen, The Netherlands

 
MOLECULAR MECHANISMS IMPACTING BCR-ABL
Scientific Working Group - Chronic myeloid leukemia
Chair: J Goldman, London, United Kingdom

• Role of BCL6
  M Muschen, San Francisco, USA
• Which signal transduction pathways are really important?
  R van Etten, Boston, USA

 

Scientific Working Group - Chronic myeloid leukemia
Chair: SL Thein, London, United Kingdom

• Transcription Factor Networks in erythropoiesis and long range genomic interactions
  E Soler, Rotterdam, The Netherlands
• Mapping the human regulatory genome
  J Stamatoyannopoulos, Washington, USA

Lunch Debates are sessions in which two opponents debate a controversial clinical or diagnostic statement.

 

IS ALLO-BMT USEFUL FOR FIRST LINE THERAPY OF MANTLE CELL LYMPHOMA?
Chair: M Dreyling, Munich, Germany

• Yes
  D Caballero, Salamanca, Spain
• No
  M Ghielmini, Bellinzona, Switzerland

 

IS CHEMOTHERAPY STILL NEEDED TO TREAT ACUTE PROMYELOCYTIC LEUKEMIA?
Chair: B Löwenberg, Rotterdam, The Netherlands

• Yes
  A Burnett, Cardiff, United Kingdom
• No
  E Estey, Seattle, USA

 

IS IRON CHELATION THERAPY USEFUL IN MDS?
Chair: E Rachmilewitz, Holon, Israel

• No
  G Garcia-Manero, Houston, USA
• Yes
  D Cilloni, Orbassano, Italy

 

LENALIDOMIDE IS THE STANDARD OF CARE IN TRANSFUSION-DEPENDENT PATIENTS WITH LOW RISK MDS ASSOCIATED WITH DEL(5Q)
Chair: M Cazzola, Pavia, Italy

• Yes
  P Fenaux, Paris, France
• No
  E Hellström-Lindberg, Stockholm, Sweden

 

MONITORING OF NEW ORAL ANTICOAGULANTS: IS IT RELEVANT?
Chair: S Middeldorp, Amsterdam, The Netherlands

• No
  G Agnelli, Perugia, Italy
• Yes
  J Harenberg, Mannheim, Germany

 

WHAT IS THE BEST TREATMENT FOR CLL WITH 17P DELETION?
Chair: P Hillmen, Leeds, United Kingdom

• FCR
  M Keating, Houston, USA
• Alemtuzumab plus SCT
  J Gribben, London, United Kingdom

Meet-the-Expert offers a small audience a highly interactive session with an authority in his or her field.

 

APLASTIC ANEMIA OR MDS - A DIAGNOSTIC AND MANAGEMENT ISSUE IN PEDIATRICS
C Niemeyer, Freiburg, Germany

 

CLINICAL PROBLEMS IN TREATMENT OF CHILDHOOD ALL
A Baruchel, Paris, France

 

DIAGNOSIS OF CONGENITAL HEMOLYTIC AND DYSERYTHROPOIETIC ANEMIAS
A Zanella, Milan, Italy

 

EPIGENETICS IN HEMATOLOGIC MALIGNANCIES
A Melnick, New York, USA

 

HOW TO INTERPRET A NEONATAL BLOOD COUNT AND SMEAR?
I Roberts, London, United Kingdom

 

INHIBITOR DEVELOPMENT IN MILD TO MODERATE HEMOPHILIA
K Fijnvandraat, Amsterdam, The Netherlands

 

MANAGEMENT OF ALL IN ADULTS
A Fielding, London, United Kingdom

 

MANAGEMENT OF HIGH RISK MPD PATIENTS
C Harrison, London, United Kingdom

 

MOLECULAR ABNORMALITIES IN AML
R Delwel, Rotterdam, The Netherlands

 

MONOCLONAL B-CELL LYMPHOCYTOSIS
P Ghia, Milan, Italy

 

MRD IN THE MANAGEMENT OF MYELOID MALIGNANCIES
D Grimwade, London, United Kingdom

 

RESISTANCE TO ANTI-PLATELET AGENTS; HOW DO WE MOVE FORWARD?
P Fontana, Geneva, Switzerland

 

RICHTER SYNDROME
G Gaidano, Novara, Italy

 

SUPPORTIVE CARE IN MULTIPLE MYELOMA
J San Miguel, Salamanca, Spain

 

SYSTEMIC MASTOCYTOSIS
L Escribano, Toledo, Spain

 

EDUCATION AND TRAINING IN EUROPEAN HEMATOLOGY
Chair: E Hellström-Lindberg, Stockholm, Sweden

• Hematological competence profiles in Europe
  E Hellström-Lindberg, Stockholm, Sweden
• Targeted education within hematology: a Virtual Masterclass
  CH Toh, Liverpool, United Kingdom
• International training in translational hematology: the TRTH program
  I Touw, Rotterdam, The Netherlands